Annexin Pharmaceuticals (OM:ANNX BTA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ANNX BTA Stock Overview

A biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases.

About the company

ANNX BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 178.06% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Annexin Pharmaceuticals AB (publ) Competitors

Cessatech

NGM:CESSA

DKK 248.3m

Pila Pharma

OM:PILA

SEK 146.5m

AlzeCure Pharma

OM:ALZCUR

SEK 167.8m

ODI Pharma

NGM:ODI

SEK 59.4m

Price History & Performance

Summary of all time highs, changes and price drops for Annexin Pharmaceuticals
Historical stock prices
Current Share Price	SEK 0.51
52 Week High	SEK 0.54
52 Week Low	SEK 0.26
Beta	1.13
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	88.54%

Recent updates

Shareholder Returns

	ANNX BTA	SE Pharmaceuticals	SE Market
7D	10.9%	1.6%	-1.5%
1Y	n/a	68.1%	23.4%

Return vs Industry: Insufficient data to determine how ANNX BTA performed against the Swedish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ANNX BTA performed against the Swedish Market.

Price Volatility

Is ANNX BTA's price volatile compared to industry and market?
ANNX BTA volatility
ANNX BTA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.6%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: ANNX BTA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ANNX BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	4	Anders Haegerstrand	www.annexinpharma.com/sv

Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein. The company offers Annexin A5 to protect and repair blood vessels and counteract inflammation.

Annexin Pharmaceuticals AB (publ) Fundamentals Summary

How do Annexin Pharmaceuticals's earnings and revenue compare to its market cap?
ANNX BTA fundamental statistics
Market cap	SEK 156.66m
Earnings (TTM)	-SEK 46.41m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.4x

P/E Ratio

Is ANNX BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANNX BTA income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 46.41m
Earnings	-SEK 46.41m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ANNX BTA perform over the long term?

See historical performance and comparison

Annexin Pharmaceuticals OM:ANNX BTA Stock Report